Pulse Biosciences, Inc. (NASDAQ:PLSE - Get Free Report) shares gapped up before the market opened on Friday . The stock had previously closed at $15.66, but opened at $16.36. Pulse Biosciences shares last traded at $16.13, with a volume of 55,647 shares traded.
Wall Street Analysts Forecast Growth
Separately, StockNews.com raised shares of Pulse Biosciences to a "sell" rating in a report on Monday.
View Our Latest Stock Report on PLSE
Pulse Biosciences Stock Performance
The business's 50-day moving average is $18.78 and its two-hundred day moving average is $18.15.
Institutional Inflows and Outflows
Institutional investors have recently added to or reduced their stakes in the stock. Tower Research Capital LLC TRC lifted its stake in Pulse Biosciences by 98.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 1,692 shares of the company's stock valued at $29,000 after buying an additional 838 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its position in Pulse Biosciences by 0.7% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 149,206 shares of the company's stock valued at $2,598,000 after purchasing an additional 1,092 shares during the last quarter. Farther Finance Advisors LLC boosted its stake in Pulse Biosciences by 44.4% during the 4th quarter. Farther Finance Advisors LLC now owns 7,220 shares of the company's stock valued at $126,000 after purchasing an additional 2,220 shares during the period. Wells Fargo & Company MN grew its position in Pulse Biosciences by 27.1% in the 4th quarter. Wells Fargo & Company MN now owns 11,315 shares of the company's stock worth $197,000 after purchasing an additional 2,416 shares during the last quarter. Finally, KLP Kapitalforvaltning AS bought a new position in Pulse Biosciences in the 4th quarter worth about $44,000. 76.95% of the stock is currently owned by institutional investors.
About Pulse Biosciences
(
Get Free Report)
Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.
Featured Articles
Before you consider Pulse Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pulse Biosciences wasn't on the list.
While Pulse Biosciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
